Vitamin D Plus Vitamin E for Eczema: A 45-Person Four-Arm Trial

Research review updated November 10, 2026. This article is educational and does not replace individualized medical care.

Nutrition claims around eczema often travel faster than the evidence. This review slows the story down and examines one trial on its own terms. The focus here is Vitamin D Plus Vitamin E for Eczema: A 45-Person Four-Arm Trial. The central distinction is between what the investigators actually compared and what readers might be tempted to infer. The study intervention was vitamin D, vitamin E, both vitamins, or double placebo; Dr. Arsy Moisturizer #003 was not used in this research and none of the study-product findings can be transferred to #003.^[1]

Evidence snapshot

Population	45 people with atopic dermatitis
Design	randomized, double-blind, placebo-controlled four-arm trial
Duration	60 days
Intervention	vitamin D, vitamin E, both vitamins, or double placebo
Main outcomes	SCORAD and blood nutrient levels
Bottom line	SCORAD decreased in each active-supplement group, with the largest percentage decrease reported in the combined group.

Why this question matters in eczema

Atopic dermatitis is a chronic, relapsing inflammatory skin disease in which barrier impairment, immune signaling, itch, sleep, infection risk, environment and treatment adherence can interact. That complexity makes adjunctive approaches attractive, but it also makes uncontrolled improvement difficult to interpret. Symptoms naturally rise and fall, background moisturizers and anti-inflammatory medicines can change outcomes, and families may alter routines simply because they are enrolled in a study. Current guidelines therefore place established topical care and age-appropriate prescription options at the center of management, while adjuncts are judged by the quality and consistency of their own evidence.^[19][20]

What the investigators tested

The investigators enrolled 45 people with atopic dermatitis and used a randomized, double-blind, placebo-controlled four-arm trial over 60 days. Participants received vitamin D, vitamin E, both vitamins, or double placebo. The prespecified or reported outcomes included SCORAD and blood nutrient levels. This design is stronger than testimonials because a concurrent comparator helps separate intervention effects from expectation, ordinary fluctuation and background care. It still does not mean every imbalance was removed, especially when the number of participants or completers was modest.^[1]

What the results showed—and did not show

SCORAD decreased in each active-supplement group, with the largest percentage decrease reported in the combined group. A statistically significant result is not automatically large enough to matter in daily life. Magnitude, confidence intervals, baseline severity, rescue-treatment rules and missing data all shape interpretation. The correct interpretation is study-specific: it supports, weakens or leaves uncertain the case for this exact intervention under these exact conditions. It does not prove that every supplement in the same broad category works, and it does not establish prevention, cure or permanent remission.^[2][3]

Cross-trial evidence is mixed. Related randomized studies have reported positive, null and subgroup-dependent findings, often using different organisms, nutrient doses, formulations, ages, background therapies and outcome scales. Reviews therefore emphasize heterogeneity and caution against selecting only favorable trials.^[4][5][6]

How large is the uncertainty?

Each arm contained only 11 or 12 participants, magnifying chance imbalances and limiting confidence in interaction claims. Other recurring issues across adjunct trials include short follow-up, incomplete blinding when products taste or feel different, numerous secondary outcomes, inconsistent rescue-medication rules, and publication bias. A p-value does not show whether the effect is durable, clinically important or reproducible. Confidence is higher when several independent, adequately powered studies converge on the same patient-important outcome.^[7][8]

Association, mechanism and causation

A plausible mechanism may involve immune signaling, microbial metabolites, fatty-acid balance, sleep regulation or nutritional status, depending on the intervention. Mechanistic plausibility is a reason to test an idea—not evidence that the idea works clinically. Changes in blood levels, microbiome composition, cytokines or colonization can occur without a meaningful improvement in eczema, and symptom improvement can occur without the proposed biomarker changing. The randomized clinical comparison remains the key causal evidence.^[9][10]

Safety boundaries for babies, children and adults

High-dose vitamin E may increase bleeding risk and vitamin D can cause toxicity; concurrent anticoagulants and other supplements require review. Infants deserve particular caution because dosing, renal and hepatic handling, formula intake, growth, immune status and infection vulnerability differ from adults. A supplement labeled “natural” can still be contaminated, mislabeled, allergenic or pharmacologically active. Anyone with pregnancy, anticoagulant use, kidney disease, immune compromise, a central line or a history of severe food allergy should obtain clinician guidance before using an oral adjunct.^[11][12]

Urgent medical assessment is appropriate for rapidly spreading redness, fever, painful blisters, eye involvement, dehydration, lethargy, poor feeding in an infant, or suspected eczema herpeticum. Supplements should never delay infection evaluation or replace prescribed anti-inflammatory treatment.

What this means for practical eczema care

The most defensible takeaway is not “supplements work” or “supplements never work.” It is that effects are intervention-specific and evidence quality varies. Discuss the exact product, strain or nutrient, dose, duration and treatment goal with a clinician. Track one or two validated outcomes, such as itch, sleep, flare frequency or POEM, while keeping established skin care stable enough to interpret change. Stop and reassess if the intervention adds cost, adverse effects or treatment complexity without a clear benefit.^[13][14]

Where Dr. Arsy #003 fits—and where it does not

Dr. Arsy Moisturizer #003 (4 oz) is a topical moisturizer for dry, sensitive and eczema-prone skin. It was not the study product in this trial. This article does not claim that #003 treats, cures or prevents eczema, reproduces an oral-supplement result, or provides an unsupported 24-hour treatment effect. A moisturizer and an oral adjunct have different roles, routes and evidence. Use #003 only according to its label and keep prescription decisions with a qualified clinician.

Related Dr. Arsy research reviews

• Probiotics for Children's Eczema: What a 70-Participant Trial Actually Measured
• Probiotics and Adult Eczema: Reading a Seven-Trial Review Without Overpromising
• Do Elimination Diets Improve Eczema? A Review of 10 Trials
• Food Allergy Testing in Eczema: What Major Guidelines Agree and Disagree On
• Choosing an Eczema Moisturizer: What 20 Studies and Guidelines Can Tell You
• Vitamin D and Eczema: What Supplement Research Actually Shows
• Omega-3 Supplements and Eczema: Questions to Ask Before Buying
• Histidine Supplements for Eczema: What the Small Crossover Pilot Can Actually Tell You

References

1. Randomized trial of vitamins D and E in atopic dermatitis. PubMed PMID 20653487.
2. Melatonin supplementation in adult atopic dermatitis: randomized clinical trial. PubMed PMID 41787942.
3. Weekly vitamin D in children with atopic dermatitis: randomized controlled trial. PubMed PMID 38483248.
4. Vitamin D for winter-related pediatric atopic dermatitis: randomized trial. PubMed PMID 25282565.
5. Vitamin D supplementation, antimicrobial peptides and atopic dermatitis. PubMed PMID 23638978.
6. Vitamin D, Staphylococcus aureus colonization and atopic dermatitis. PubMed PMID 26817206.
7. Sea buckthorn seed and pulp oils in atopic dermatitis. PubMed PMID 15539258.
8. Dietary hempseed oil in patients with atopic dermatitis. PubMed PMID 16019622.
9. Long-chain omega-3 fatty acids in atopic dermatitis: multicenter trial. PubMed PMID 8011502.
10. Omega-3 fatty-acid supplementation in atopic dermatitis. PubMed PMID 2650695.
11. Essential fatty-acid supplementation in atopic dermatitis: placebo trial. PubMed PMID 8099640.
12. DHA supplementation in atopic eczema: randomized controlled trial. PubMed PMID 18241260.
13. Cochrane review: dietary supplements for established atopic eczema. PubMed PMID 22336810.
14. Systematic review of oral vitamins and supplements in atopic dermatitis. PubMed PMID 30892697.
15. Systematic review of nutritional supplements in atopic dermatitis. PubMed PMID 38019566.
16. EAACI review of nutritional interventions in children with atopic dermatitis. PubMed PMID 38783644.
17. Diet and eczema: review of dietary supplements. PubMed PMID 27648380.
18. Dietary elimination for atopic dermatitis: systematic review and meta-analysis. PubMed PMID 35987995.
19. American Academy of Dermatology guideline: topical therapy in adults with atopic dermatitis. PubMed PMID 36641009.
20. Current pediatric atopic dermatitis guideline. PubMed PMID 41949508.
21. Cochrane review of emollients and moisturizers for eczema. PubMed PMID 28432721.

Editorial standard: Claims were limited to the cited study designs. Positive, null and uncertain results were retained. Study products were not equated with Dr. Arsy #003.